

**Therapeutic Drug Monitoring Market by Product (Equipments, Consumables), Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs, Anti-Arrhythmic Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user - Global Forecast to 2029**

Market Report | 2024-12-18 | 381 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

It is anticipated that the therapeutic drug monitoring market will grow from USD 2.30 billion in 2024 to USD 3.44 billion by 2029, with a steady compound annual growth rate (CAGR) of 8.4%. Advancements in immunoassay techniques remain a key driver of this growth, influencing the sector's trajectory in a positive manner. These techniques aim to improve the accuracy, speed, and specificity of medication monitoring, including enhanced chemiluminescence, ELISA, and fluorescence enhancement. In the meantime, healthcare professionals are becoming more aware of the significance of TDM in improving therapeutic outcomes, leading to its incorporation into clinical settings. Education and training initiatives have raised clinicians' understanding of the advantages of TDM, making it easier for the technology to be implemented in everyday patient care. Collaboratively, these elements are influencing a dynamic and growing market environment.

"Consumables segment is expected to grow at the highest CAGR during the forecast period, by product."

The consumables segment holds the highest CAGR in the therapeutic drug monitoring. Consumables such as reagents, assay kits, and calibrators create a very important part in the TDM market as they are integral in routine monitoring of drugs for chronic but complex-to-cure conditions such as cancer, cardiovascular, and neurological disorders. Demand for high-quality consumables is growing as a result of the increased focus on customized therapy and the need for precise medication level evaluation.

Additionally, spending money on advanced TDM systems produced by labs and hospitals would raise demand for its related goods, which would support market expansion.

"Blood segment is expected to hold the largest share of TDM market during the forecast period, by specimen."

Blood, as it is the most used specimen for TDM, fuels the market owing to its capability to provide precise and direct

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

measurement of drug concentrations in plasma or serum. Well-established protocols in the collection and processing of blood ensure that it is reliable and consistent, while its wide clinical acceptance is well established. It is compatible with the most advanced technologies, including immunoassays and LC-MS/MS, by which drugs can be accurately quantified, meeting modern demands in therapeutic monitoring. Besides, this is supported by regulatory guidelines and clinical practices, which favor blood-based TDM; it has proved its merit in monitoring pharmacokinetics for the optimization of dose, which improves therapeutic outcomes, all combining to favor its adoption in a clinical setting.

"US to grow at the highest CAGR for North America therapeutic drug monitoring market"

The increasing prevalence in the US of chronic diseases of a cardiovascular nature, diabetes, neurological disorders, and cancer, among many others, significantly fuels this demand for TDM. Several of these disorders require thorough monitoring for the optimization of their treatment efficacy by taking measures to reduce adverse events, hence increasing the pace of adoption of TDM technologies. The well-established and well-developed healthcare framework of the country involves large numbers of hospitals, laboratories, and diagnostic centers, which further fortifies the integration of advanced end. Besides, continuous innovation in TDM technologies, supported by the presence of numerous pharmaceutical and biotech companies, ensures availability and advances in monitoring tools. These are all factors combined to spur the rapid growth of the TDM market in the US.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the therapeutic drug monitoring marketplace.

-□By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%

-□By Designation: C-level Executives - 30%, Directors - 34%, and Others - 36%

-□By Region: North America- 40%, Europe - 25%, Asia Pacific- 19%, Latin America- 8%, Middle East & Africa- 6% and GCC Countries- 2%

The companies included in Therapeutic Drug Monitoring market are Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMérieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK), apDia Group (Belgium), BBI Solutions (UK), Eagle Biosciences, Inc. (US), Jasem Laboratory Systems and Solutions (Turkey), Aalto Scientific, Ltd. (US), Immundiagnostik AG (Germany), UTAK (US), Sekisui Medical Co., Ltd. (Japan), DiaSystem Scandinavia AB (Sweden), Cambridge Life Sciences Limited (UK), Chromsystems Instruments & Chemicals GmbH (Germany), BUHLMANN Laboratories AG (Switzerland), SJK Global, LLC (US), Epitope Diagnostics, Inc. (US), QED Bioscience Inc. (US), Boditech Med Inc. (South Korea), and Immunodiagnostic Systems (UK).

#### Research Coverage

This research report categorizes the therapeutic drug monitoring market by product (Equipment, and Consumables), by technology (Immunoassays, Chromatography-MS, and Other Technologies), by Drug Class (Anti-Epileptic Drugs, Anti-Arhythmic Drugs, Immunosuppressant Drugs, Antibiotic Drugs, Bronchodilator Drugs, Psychoactive Drugs, and Other Drug Classes), by Therapeutic Area (Neurological Disorders□, Cardiology, Infectious Diseases, Oncology, Other Therapeutic Areas), by Specimen (Blood, Saliva, and other samples), by End User (Hospital Laboratories, Commercial & Private Laboratories, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the therapeutic drug monitoring market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the therapeutic drug monitoring market. Competitive analysis of upcoming startups in the therapeutic drug monitoring market ecosystem is covered in this report.

#### Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall therapeutic drug monitoring market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report provides insights on the following pointers:

-□Analysis of key drivers (Importance of therapeutic drug monitoring in organ transplant procedures, Use of therapeutic drug monitoring across various therapeutic fields, Increasing preferences for precision medicine, Growing focus on R&D related to therapeutic drug monitoring, Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, Increase in prevalence of Epilepsy, Rising prevalence of cancer to drive adoption of Therapeutic Drug Monitoring in Oncology Treatments), restraints (High capital investments, Reluctance of small hospitals to offer therapeutic drug monitoring services), opportunities (Significant opportunities in BRICS countries, Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring, Integration of AI and machine learning), and challenges (Alternatives to conventional therapeutic drug monitoring, Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries, Shortage of skilled professionals) influencing the growth of the therapeutic drug monitoring market.

-□Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the therapeutic drug monitoring market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the therapeutic drug monitoring market across varied regions.

-□Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the therapeutic drug monitoring market

-□Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Abbott (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), bioMerieux SA (France), Biosynex SA (France), Grifols, S.A. (Spain), Exagen Inc. (US), ARK Diagnostics, Inc. (US), R-Biopharm AG (Germany), and Randox Laboratories Ltd. (UK)) among others in therapeutic drug monitoring market.

## **Table of Contents:**

1□INTRODUCTION□	33
1.1□STUDY OBJECTIVES□	33
1.2□MARKET DEFINITION□	33
1.3□STUDY SCOPE□	34
1.3.1□MARKETS COVERED□	34
1.3.2□INCLUSIONS AND EXCLUSIONS OF STUDY□	35
1.3.3□YEARS CONSIDERED□	35
1.3.4□CURRENCY CONSIDERED□	36
1.4□STAKEHOLDERS□	36
1.5□SUMMARY OF CHANGES□	36
2□RESEARCH METHODOLOGY□	37
2.1□RESEARCH DATA□	37
2.1.1□SECONDARY DATA□	38
2.1.1.1□Key data from secondary sources□	39
2.1.2□PRIMARY DATA□	40
2.1.2.1□Primary sources□	40
2.1.2.2□Key data from primary sources□	41
2.1.2.3□Key industry insights□	42
2.1.2.4□Breakdown of primary interviews□	43
2.2□MARKET SIZE ESTIMATION□	43
2.2.1□BOTTOM-UP APPROACH□	44
2.2.1.1□Approach 1: Company revenue estimation approach□	44
2.2.1.2□Approach 2: Lab-based analysis□	45

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.2.1.3	Approach 3: Drug class-based analysis	46
2.2.1.4	Approach 4: Presentations of companies and primary interviews	46
2.2.1.5	Growth forecast	47
2.2.1.6	CAGR projections	47
2.2.2	TOP-DOWN APPROACH	48
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	49
2.4	MARKET SHARE ASSESSMENT	50
2.5	RESEARCH ASSUMPTIONS	50
2.6	STUDY LIMITATIONS	50
2.7	GROWTH RATE ASSUMPTIONS	51
2.8	RISK ASSESSMENT	51
3	EXECUTIVE SUMMARY	52
?		
4	PREMIUM INSIGHTS	58
4.1	THERAPEUTIC DRUG MONITORING MARKET OVERVIEW	58
4.2	ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SHARE, BY DRUG CLASS AND COUNTRY (2023)	59
4.3	THERAPEUTIC DRUG MONITORING MARKET, BY KEY COUNTRY	60
4.4	THERAPEUTIC DRUG MONITORING MARKET: REGIONAL MIX, 2024-2029	61
4.5	THERAPEUTIC DRUG MONITORING MARKET: DEVELOPING VS. DEVELOPED MARKETS	62
5	MARKET OVERVIEW	63
5.1	INTRODUCTION	63
5.2	MARKET DYNAMICS	64
5.2.1	DRIVERS	64
5.2.1.1	Importance of therapeutic drug monitoring in organ transplant procedures	64
5.2.1.2	Use of therapeutic drug monitoring across various therapeutic fields	65
5.2.1.3	Increasing preference for precision medicine	67
5.2.1.4	Growing focus on R&D related to therapeutic drug monitoring	68
5.2.1.5	Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis	69
5.2.1.6	Increasing prevalence of epilepsy	70
5.2.1.7	Rising prevalence of cancer	71
5.2.2	RESTRAINTS	72
5.2.2.1	High capital investments	72
5.2.2.2	Reluctance of small hospitals to offer therapeutic drug monitoring services	73
5.2.3	OPPORTUNITIES	73
5.2.3.1	Significant opportunities in BRICS countries	73
5.2.3.2	Innovations in immunoassay technologies to improve accuracy and speed of drug monitoring	74
5.2.3.3	Integration of AI and machine learning	75
5.2.4	CHALLENGES	76
5.2.4.1	Alternatives to conventional therapeutic drug monitoring	76
5.2.4.2	Operational challenges and inadequate infrastructure to restrict TDM testing in low- and middle-income countries	76
5.2.4.3	Shortage of skilled professionals	77
5.3	PRICING ANALYSIS	77
5.4	VALUE CHAIN ANALYSIS	79

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.5	SUPPLY CHAIN ANALYSIS	80
5.6	ECOSYSTEM ANALYSIS	81
5.7	REGULATORY LANDSCAPE	82
5.7.1	NORTH AMERICA	86
5.7.1.1	US	86
5.7.1.2	Canada	87
5.7.2	EUROPE	88
5.7.3	ASIA PACIFIC	88
5.7.3.1	China	88
5.7.3.2	Japan	89
5.7.3.3	India	89
5.7.4	LATIN AMERICA	90
5.7.5	MIDDLE EAST	90
5.7.6	AFRICA	90
5.8	TRADE ANALYSIS	91
5.9	PATENT ANALYSIS	92
5.10	KEY CONFERENCES AND EVENTS IN 2025 AND 2026	93
5.11	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	94
5.12	TECHNOLOGY ANALYSIS	95
5.12.1	KEY TECHNOLOGY	95
5.12.1.1	Enzyme-linked immunosorbent assay	95
5.12.2	COMPLEMENTARY TECHNOLOGY	96
5.12.2.1	Liquid chromatography-mass spectrometry	96
5.12.3	ADJACENT TECHNOLOGY	96
5.12.3.1	Electrophoresis	96
5.13	PORTER'S FIVE FORCES ANALYSIS	97
5.13.1	THREAT OF NEW ENTRANTS	98
5.13.2	INTENSITY OF COMPETITIVE RIVALRY	98
5.13.3	BARGAINING POWER OF BUYERS	98
5.13.4	BARGAINING POWER OF SUPPLIERS	98
5.13.5	THREAT OF SUBSTITUTES	98
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	99
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	99
5.14.2	BUYING CRITERIA	99
5.15	INVESTMENT AND FUNDING SCENARIO	100
5.16	IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE (AI) ON THERAPEUTIC DRUG MONITORING MARKET	100
6	THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT	102
6.1	INTRODUCTION	103
6.2	CONSUMABLES	103
6.2.1	REPEAT PURCHASES AND HIGH USAGE TO DRIVE MARKET	103
6.3	EQUIPMENT	105
6.3.1	IMMUNOASSAY ANALYZERS	108
6.3.1.1	High efficiency to drive adoption	108
6.3.2	CHROMATOGRAPHY & MS DETECTORS	111
6.3.2.1	Technological advancements to propel growth	111
?		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3.3	CLINICAL CHEMISTRY ANALYZERS	114
6.3.3.1	Increasing incidence of chronic and complex diseases to drive market	114
7	THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY	117
7.1	INTRODUCTION	118
7.2	IMMUNOASSAYS	118
7.2.1	ENZYLE-LINKED IMMUNOSORBENT ASSAYS	121
7.2.1.1	Accurate measurement of target-specific proteins to drive market	121
7.2.2	CHEMILUMINESCENCE IMMUNOASSAYS	123
7.2.2.1	Rapid detection time and good specificity to support growth	123
7.2.3	FLUORESCENCE IMMUNOASSAYS	127
7.2.3.1	High operability and better sensitivity of FIAs to drive market	127
7.2.4	COLORIMETRIC IMMUNOASSAYS	130
7.2.4.1	Demand for colorimetric immunoassays to decline due to rising preference for advanced equipment	130
7.2.5	OTHER IMMUNOASSAYS	132
7.3	CHROMATOGRAPHY-MS	134
7.3.1	LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY	137
7.3.1.1	High accuracy to drive demand for LC-MS	137
7.3.2	GAS CHROMATOGRAPHY-MASS SPECTROMETRY	140
7.3.2.1	Drawbacks of GC-MS to challenge market growth	140
7.4	OTHER TECHNOLOGIES	142
8	THERAPEUTIC DRUG MONITORING MARKET, BY DRUG CLASS	146
8.1	INTRODUCTION	147
8.2	ANTIEPILEPTIC DRUGS	147
8.2.1	HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE GROWTH	147
8.3	ANTIARRHYTHMIC DRUGS	150
8.3.1	INCREASING INCIDENCE OF HEART DISORDERS TO BOOST DEMAND	150
8.4	IMMUNOSUPPRESSANT DRUGS	154
8.4.1	INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES TO DRIVE MARKET	154
8.5	ANTIBIOTIC DRUGS	157
8.5.1	TECHNOLOGICAL ADVANCEMENTS TO PROPEL DEMAND	157
8.6	BRONCHODILATOR DRUGS	160
8.6.1	RISING PREVALENCE OF RESPIRATORY DISEASES TO ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING	160
8.7	PSYCHOACTIVE DRUGS	163
8.7.1	RISING CASES OF MENTAL ILLNESS TO AUGMENT MARKET GROWTH	163
8.8	OTHER DRUGS	166
9	THERAPEUTIC DRUG MONITORING MARKET, BY THERAPEUTIC AREA	170
9.1	INTRODUCTION	171
9.2	NEUROLOGICAL DISORDERS	171
9.2.1	INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO PROPEL MARKET	171
9.3	CARDIOLOGY	174
9.3.1	HIGH BURDEN OF CARDIOVASCULAR DISEASES TO DRIVE MARKET	174
9.4	INFECTIOUS DISEASES	176

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.4.1	INCREASING PREVALENCE OF TB AND HEPATITIS TO BOOST DEMAND	176
9.5	ONCOLOGY	179
9.5.1	RIISING BURDEN OF CANCER AND GROWING EMPHASIS ON PERSONALIZED MEDICINE TO PROPEL MARKET	179
9.6	OTHER THERAPEUTIC AREAS	182
10	THERAPEUTIC DRUG MONITORING MARKET, BY SPECIMEN	185
10.1	INTRODUCTION	186
10.2	BLOOD	186
10.2.1	INNOVATIONS IN BLOOD SAMPLING TECHNIQUES TO DRIVE MARKET	186
10.3	SALIVA	188
10.3.1	DEVELOPMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO DRIVE MARKET	188
10.4	OTHER SAMPLES	190
11	THERAPEUTIC DRUG MONITORING MARKET, BY END USER	193
11.1	INTRODUCTION	194
11.2	HOSPITAL LABORATORIES	194
11.2.1	INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS PERFORMED TO DRIVE MARKET	194
11.3	COMMERCIAL & PRIVATE LABORATORIES	197
11.3.1	EXTENSIVE TEST MENU OF COMMERCIAL & PRIVATE LABS TO SUSTAIN DEMAND FOR SERVICES	197
11.4	OTHER END USERS	199
12	THERAPEUTIC DRUG MONITORING MARKET, BY REGION	202
12.1	INTRODUCTION	203
12.2	NORTH AMERICA	203
12.2.1	NORTH AMERICA: MACROECONOMIC OUTLOOK	204
12.2.2	US	210
12.2.2.1	Increasing awareness regarding precision medicine to propel market	210
12.2.3	CANADA	215
12.2.3.1	Availability of funding for research to offer growth opportunities	215
	?	
12.3	EUROPE	220
12.4	EUROPE: MACROECONOMIC OUTLOOK	221
12.4.1	GERMANY	226
12.4.1.1	Rising prevalence of chronic medical conditions such as cancer and diabetes to support market growth	226
12.4.2	UK	230
12.4.2.1	Increasing cases of chronic diseases to drive market	230
12.4.3	FRANCE	235
12.4.3.1	Rising awareness of benefits of therapeutic drug monitoring to accelerate demand	235
12.4.4	ITALY	239
12.4.4.1	Rising incidence of cancer to drive demand	239
12.4.5	SPAIN	244
12.4.5.1	Adoption of technologically advanced immunoassays to boost market	244
12.4.6	REST OF EUROPE	249
12.5	ASIA PACIFIC	253
12.6	ASIA PACIFIC: MACROECONOMIC OUTLOOK	253
12.6.1	JAPAN	259
12.6.1.1	High prevalence of chronic diseases and advanced healthcare infrastructure to drive market	259
12.6.2	CHINA	264

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.6.2.1	Rising number of organ transplants to boost market	264
12.6.3	INDIA	268
12.6.3.1	Rising incidence of cancer to propel market	268
12.6.4	AUSTRALIA	273
12.6.4.1	High healthcare expenditure and favorable government initiatives to propel market	273
12.6.5	REST OF ASIA PACIFIC	278
12.7	LATIN AMERICA	282
12.7.1	INCREASING BURDEN OF CHRONIC CONDITIONS AND EXPANDING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET	282
12.7.2	LATIN AMERICA: MACROECONOMIC OUTLOOK	284
12.8	MIDDLE EAST & AFRICA	288
12.8.1	INCREASING NUMBER OF CANCER PATIENTS TO DRIVE MARKET	288
12.8.2	MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK	290
12.9	GCC COUNTRIES	294
12.9.1	GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH	294
12.9.2	GCC COUNTRIES: MACROECONOMIC OUTLOOK	296
	?	
13	COMPETITIVE LANDSCAPE	301
13.1	OVERVIEW	301
13.2	RIGHT TO WIN	301
13.3	STRATEGIES ADOPTED BY KEY PLAYERS	301
13.4	REVENUE ANALYSIS	303
13.5	MARKET SHARE ANALYSIS	304
13.6	COMPANY EVALUATION MATRIX: KEY PLAYERS	305
13.6.1	STARS	306
13.6.2	EMERGING LEADERS	306
13.6.3	PERVASIVE PLAYERS	306
13.6.4	PARTICIPANTS	306
13.6.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	308
13.6.5.1	Company footprint	308
13.6.5.2	Region footprint	308
13.6.5.3	Product footprint	309
13.6.5.4	Technology footprint	309
13.6.5.5	End-user footprint	310
13.7	COMPANY EVALUATION MATRIX: STARTUPS/SMES	310
13.7.1	PROGRESSIVE COMPANIES	310
13.7.2	RESPONSIVE COMPANIES	310
13.7.3	DYNAMIC COMPANIES	311
13.7.4	STARTING BLOCKS	311
13.7.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	312
13.7.5.1	Detailed list of key startups/SMEs	312
13.8	COMPANY VALUATION & FINANCIAL METRICS	312
13.8.1	FINANCIAL METRICS	312
13.8.2	COMPANY VALUATION	313
13.9	PRODUCT/BRAND COMPARISON	313
13.10	COMPETITIVE SCENARIO	314
13.10.1	PRODUCT LAUNCHES	314

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



13.10.2	DEALS	315
13.10.3	EXPANSIONS	315
14	COMPANY PROFILES	316
14.1	KEY PLAYERS	316
14.1.1	ABBOTT	316
14.1.1.1	Business overview	316
14.1.1.2	Products offered	317
14.1.1.3	MnM view	318
14.1.1.3.1	Key strengths	318
14.1.1.3.2	Strategic choices	318
14.1.1.3.3	Weaknesses and competitive threats	318
14.1.2	THERMO FISHER SCIENTIFIC INC.	319
14.1.2.1	Business overview	319
14.1.2.2	Products offered	320
14.1.2.3	Recent developments	322
14.1.2.3.1	Product launches	322
14.1.2.3.2	Deals	322
14.1.2.4	MnM view	323
14.1.2.4.1	Key strengths	323
14.1.2.4.2	Strategic choices	323
14.1.2.4.3	Weaknesses and competitive threats	323
14.1.3	F. HOFFMANN-LA ROCHE LTD.	324
14.1.3.1	Business overview	324
14.1.3.2	Products offered	326
14.1.3.3	Recent developments	327
14.1.3.3.1	Product launches	327
14.1.3.3.2	Deals	327
14.1.3.4	MnM view	327
14.1.3.4.1	Key strengths	327
14.1.3.4.2	Strategic choices	327
14.1.3.4.3	Weaknesses and competitive threats	327
14.1.4	SIEMENS HEALTHINEERS AG	328
14.1.4.1	Business overview	328
14.1.4.2	Products offered	330
14.1.4.3	Recent developments	331
14.1.4.3.1	Product launches	331
14.1.4.3.2	Deals	332
14.1.4.4	MnM view	332
14.1.4.4.1	Key strengths	332
14.1.4.4.2	Strategic choices	332
14.1.4.4.3	Weaknesses and competitive threats	332
14.1.5	DANAHER CORPORATION	333
14.1.5.1	Business overview	333
14.1.5.2	Products offered	334
14.1.5.3	Recent developments	335
14.1.5.3.1	Product launches	335
14.1.5.3.2	Deals	336

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

14.1.5.4	MnM view	336
14.1.5.4.1	Key strengths	336
14.1.5.4.2	Strategic choices	336
14.1.5.4.3	Weaknesses and competitive threats	337
	?	
14.1.6	BIO-RAD LABORATORIES, INC.	338
14.1.6.1	Business overview	338
14.1.6.2	Products offered	339
14.1.6.3	Recent developments	341
14.1.6.3.1	Product launches	341
14.1.6.3.2	Deals	341
14.1.7	BIOMERIEUX SA	342
14.1.7.1	Business overview	342
14.1.7.2	Products offered	344
14.1.8	BIOSYNEX SA	345
14.1.8.1	Business overview	345
14.1.8.2	Products offered	346
14.1.8.3	Recent developments	347
14.1.8.3.1	Product launches	347
14.1.8.3.2	Deals	347
14.1.9	GRIFOLS, S.A.	348
14.1.9.1	Business overview	348
14.1.9.2	Products offered	350
14.1.9.3	Recent developments	350
14.1.9.3.1	Deals	350
14.1.10	EXAGEN INC.	351
14.1.10.1	Business overview	351
14.1.10.2	Products offered	352
14.1.10.3	Recent developments	352
14.1.10.3.1	Deals	352
14.1.11	ARK DIAGNOSTICS, INC.	353
14.1.11.1	Business overview	353
14.1.11.2	Products offered	353
14.1.12	R-BIOPHARM AG	355
14.1.12.1	Business overview	355
14.1.12.2	Products offered	355
14.1.12.3	Recent developments	356
14.1.12.3.1	Product launches	356
14.1.13	RANDOX LABORATORIES LTD.	357
14.1.13.1	Business overview	357
14.1.13.2	Products offered	357
14.2	OTHER PLAYERS	359
14.2.1	APDIA GROUP	359
14.2.2	BBI SOLUTIONS	359
14.2.3	EAGLE BIOSCIENCES, INC.	360
14.2.4	ASEM LABORATORY SYSTEMS AND SOLUTIONS	362
14.2.5	AALTO SCIENTIFIC, LTD.	362

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

14.2.6	IMMUNDIAGNOSTIK AG	363
14.2.7	UTAK	364
14.2.8	SEKISUI MEDICAL CO., LTD.	365
14.2.9	DIASYSTEM SCANDINAVIA AB	366
14.2.10	CAMBRIDGE LIFE SCIENCES LIMITED	367
14.2.11	CHROMSYSTEMS INSTRUMENTS & CHEMICALS GMBH	367
14.2.12	BUHLMANN LABORATORIES AG	368
14.2.13	SJK GLOBAL, LLC	368
14.2.14	EPITOPE DIAGNOSTICS, INC.	369
14.2.15	QED BIOSCIENCE INC.	369
14.2.16	BODITECH MED INC.	370
14.2.17	IMMUNODIAGNOSTIC SYSTEMS	371
15	APPENDIX	372
15.1	DISCUSSION GUIDE	372
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	377
15.3	CUSTOMIZATION OPTIONS	379
15.4	RELATED REPORTS	379
15.5	AUTHOR DETAILS	380

**Therapeutic Drug Monitoring Market by Product (Equipments,Consumables),  
Technology (Immunoassays), Drug Class (Anti-Epileptic Drugs,Anti-Arrhythmic  
Drugs), Therapeutic Area (Oncology, Cardiology), Specimen (Blood), End user -  
Global Forecast to 2029**

Market Report | 2024-12-18 | 381 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>